The Evolution of Multiple Myeloma Patient Management: Managing Today, Preparing for Tomorrow

Access Activity

Overview / Abstract:

The clinical multiple myeloma arena has undergone significant advances in diagnosis and prognosis, minimal residual disease monitoring, and supportive care. This expansion brings renewed hope to patients, but it presents new challenges for the clinicians charged with their care. Some patients enjoy many years in clinical remission, whereas for others survival is no more than 2 or 3 years. This reflects the heterogeneity of myeloma and underscores the inappropriateness of a one-size-fits-all management approach. Improving patient outcomes requires building on the foundation of current therapies and ensuring that clinicians are equipped with the knowledge and strategies needed to provide patients with a more personalized approach to treatment. Oncology clinicians have a growing array of tools at their disposal to favorably influence a patient’s quality and quantity of life—but they can only take advantage of these tools by remaining current on the latest research and understanding the appropriate timing and strategies for using newer therapies.


Dec 31, 2019


Nurse Practitioner , Physician CME, Physician Assistant CME


Online, Webinar / Webcast / Video

Credits / Hours

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.Penn State College of Medicine designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Presenters / Authors / Faculty

Paul G. Richardson, MD—Program Co-Chair
R. J. Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader and Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

A. Keith Stewart, MBChB, MRCP, FRCPC, MBA—Program Co-Chair
Carlson and Nelson Endowed Director
Center for Individualized Medicine
Vasek and Anna Maria Polak Professor of Cancer Research
Consultant, Division of Hematology/Oncology
Mayo Clinic
Scottsdale, Arizona

Ajai Chari, MD
Associate Professor of Medicine
Director of Clinical Research, Multiple Myeloma Program
Icahn School of Medicine at Mount Sinai
New York, New York

C. Ola Landgren, MD, PhD
Chief, Myeloma Service
Professor of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

María-Victoria Mateos, MD, PhD
Associate Professor of Hematology
Director, Myeloma Unit
University Hospital of Salamanca
Salamanca, Spain

Gregory J. Orloff, MD
Member, Multiple Myeloma Research Consortium
Virginia Cancer Specialists
Assistant Professor of Oncology
Fairfax, Virginia

Activity Specialities / Related Topics

Education / Teaching, Hematology, Oncology / Cancer / Radiation Therapy

Sponsors / Supporters / Grant Providers

Support for this activity has been provided through educational grants from Adaptive Biotechnologies, Amgen, and Celgene Corporation.

Keywords / Search Terms

RedMedEd MMRF, MM, multiple myeloma, imaging procedures, cytogenetics, genomics, testing tools, patient prognosis, risk stratification, combination, frontline, risk, patient, characteristics, minimal residual disease, MRD, maintenance therapy, novel agent, monoclonal antibody, relapsed/refractory, RR, genomics, clinical trials, small-molecule inhibitors, inhibitors, immune, oncology, treatment regimens, RedMedEd, PSCM, Free, Free CME Free CE CME

Access Activity

RXinsider,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps. RXinsider,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the Terms of Service. Site Map.